Barclays PLC Boosts Position in Structure Therapeutics Inc. (NASDAQ:GPCR)

Barclays PLC raised its stake in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 64.5% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 81,138 shares of the company's stock after buying an additional 31,815 shares during the period. Barclays PLC owned about 0.14% of Structure Therapeutics worth $3,562,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently added to or reduced their stakes in GPCR. Sandia Investment Management LP purchased a new position in shares of Structure Therapeutics during the second quarter valued at $39,000. Assetmark Inc. lifted its stake in shares of Structure Therapeutics by 120.0% in the 3rd quarter. Assetmark Inc. now owns 1,318 shares of the company's stock valued at $58,000 after purchasing an additional 719 shares during the period. Quarry LP purchased a new stake in shares of Structure Therapeutics during the second quarter worth about $79,000. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Structure Therapeutics by 60.1% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company's stock worth $158,000 after acquiring an additional 1,420 shares during the last quarter. Finally, Dearborn Partners LLC acquired a new position in shares of Structure Therapeutics in the 3rd quarter worth approximately $202,000. 91.78% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on GPCR shares. Morgan Stanley began coverage on shares of Structure Therapeutics in a research report on Monday, September 23rd. They set an "overweight" rating and a $118.00 price objective for the company. Cantor Fitzgerald reissued an "overweight" rating and issued a $65.00 target price on shares of Structure Therapeutics in a report on Monday, September 23rd. JMP Securities reissued a "market outperform" rating and issued a $91.00 price objective on shares of Structure Therapeutics in a research note on Wednesday, December 18th. Finally, HC Wainwright restated a "buy" rating and issued a $80.00 target price on shares of Structure Therapeutics in a research note on Thursday. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, Structure Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $86.50.

Structure Therapeutics Stock Performance

Structure Therapeutics stock traded up $0.68 during midday trading on Monday, reaching $28.58. The company's stock had a trading volume of 697,100 shares, compared to its average volume of 802,295. Structure Therapeutics Inc. has a fifty-two week low of $26.23 and a fifty-two week high of $62.74. The firm has a market capitalization of $1.64 billion, a PE ratio of -38.62 and a beta of -3.41. The stock's 50 day simple moving average is $35.32 and its 200 day simple moving average is $38.63.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.